Together these data suggest that critical regulatory components of the Hh signaling pathway, such as GLI2, represent part of a core transcriptional program driving human myeloid LSC maintenance for BC CML, thereby providing the impetus for testing the capacity of a selective SMO antagonist to eradicate LSC. This evidence concerns the gene SMO and chronic myelogenous leukemia, BCR-ABL1 positive.